Higher Blood Vascular Cell Adhesion Molecule-1 is Related to the Increased Risk of Cardiovascular Events in Chronic Obstructive Pulmonary Disease
Authors Li J, Wang Q, Zhang Q, Wang Z, Wan X, Miao C, Zeng Z
Received 28 May 2020
Accepted for publication 6 September 2020
Published 28 September 2020 Volume 2020:15 Pages 2289—2295
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Jinlin Li,1 Qi Wang,1 Qingping Zhang,2 Zhengyan Wang,1 Xin Wan,3 Chenfang Miao,4 Xi Zeng5
1Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei 441300, People’s Republic of China; 2Department of Otolaryngology Head and Neck Surgery, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei 441300, People’s Republic of China; 3Department of Critical Care Medicine, Mindong Hospital of Fujian Medical University, Fuan, Fujian 355000, People’s Republic of China; 4Department of Anesthesiology, Mindong Hospital of Fujian Medical University, Fuan, Fujian 355000, People’s Republic of China; 5Department of Geriatrics, Mindong Hospital of Fujian Medical University, Fuan, Fujian 355000, People’s Republic of China
Correspondence: Xi Zeng
Department of Geriatrics, Mindong Hospital of Fujian Medical University, No. 89 Heshan Road, Fuan City 355000, Fujian Province, People’s Republic of China
Tel +86 18596658975
Background: Vascular cell adhesion molecule-1 (VCAM-1) is associated with vascular-related inflammation and atherosclerosis. This study aimed to evaluate whether VCAM-1 can be used for an indication of increased risk of CV events in patients with COPD.
Methods: Serum VCAM-1 levels were measured in 163 COPD patients. All COPD patients were prospectively followed up for a median period of 48 months (range=3– 54). Cox proportional hazard analysis was performed to evaluate the prognostic value of serum VCAM-1 for predicting CV events.
Results: Serum VCAM-1 levels were higher in COPD patients with CV events than in those without CV events (1174.4± 365.3 ng/mL vs 947.8± 293.2 ng/mL; P< 0.001). The logistic regression analysis revealed that serum VCAM-1 (OR=1.750; 95% CI, 1.324– 2.428; Ptrend= 0.0012) was independently associated with CVD (cardiovascular disease) history after adjusting for age, sex, BMI, current smoker, current drinker, admission systolic and diastolic BP, LVEF and laboratory measurements in patients with COPD at baseline. The Kaplan–Meier analysis demonstrated that the rate of CV events was higher in COPD patients with serum VCAM-1 levels above the median (517.3 ng/mL) than in those with VCAM-1 levels below the median. The Cox proportional hazard analysis revealed that serum VCAM-1 (HR=2.617; 95% CI, 1.673– 5.328; Ptrend< 0.001) may be an independent prognostic factor for CV events in the COPD patients.
Conclusion: Our results suggested that serum VCAM-1 was significantly and independently associated with CV events in COPD patients. The inflammatory marker may help clinicians predict CV complications early.
Keywords: vascular cell adhesion molecule-1, chronic obstructive pulmonary disease, cardiovascular events, prognostic value